ALERTEC TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

MODAFINIL

제공처:

TEVA CANADA LIMITED

ATC 코드:

N06BA07

INN (International Name):

MODAFINIL

복용량:

100MG

약제 형태:

TABLET

구성:

MODAFINIL 100MG

관리 경로:

ORAL

패키지 단위:

30

처방전 유형:

Prescription

치료 영역:

Wakefulness-Promoting Agents

제품 요약:

Active ingredient group (AIG) number: 0136083001; AHFS:

승인 상태:

APPROVED

승인 날짜:

2012-01-03

제품 특성 요약

_ _
_Product Monograph _
_ _
_ALERTEC modafinil _
_Page 1 of 45 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ALERTEC
®*
modafinil
Tablets, 100 mg, Oral
Mfr. Std.
Central Nervous System Stimulant
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada M1B 2K9
Marketed by:
Teva Canada Innovation
Montréal, Quebec
H2Z 1S8
Date of Initial Authorization:
February 26, 1999
Date of Revision:
July 4, 2023
Submission Control Number: 272079
*
ALERTEC is a registered trademark of Cephalon, Inc. Used under license
by Teva Canada Innovation.
_ _
_Product Monograph _
_ _
_ALERTEC modafinil _
_Page 2 of 45 _
RECENT MAJOR LABEL CHANGES
4 Dosage and Administration
11/2021
7 Warnings and Precautions, Alcohol Consumption, Risk of
stroke
11/2021
7 Warnings and Precautions, Dependence/Tolerance
07/2023
9 Drug-Behavioural Interactions – Alcohol Consumption
07/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT
LISTED.
RECENT MAJOR LABEL CHANGES
......................................................................................
2
TABLE OF CONTENTS
...........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
.............................................................................................................
4
1.2
Geriatrics
.............................................................................................................
5
2
CONTRAINDICATIONS
................................................................................................
5
4
DOSAGE AND ADMINISTRATION
..............................................................................
5
4.1
Dosing Considerations
...................................................................